← Therapy pipeline
Investigational · Obesity development

VRB-101

Oral ecnoglutide · Ecnoglutide oral · XW004 · Verdiva Bio

A once-weekly oral formulation of ecnoglutide, a GLP-1 peptide analogue.

GLP-1
Obesity stagePhase 2Updated as of November 2026
SponsorVerdiva Bio
TargetsGLP-1
RouteOral tablet
DevelopmentObesity-specific
01 / Evidence

Results availability

No numerical results shown

No numerical study results are currently summarized for this profile. The development stage and linked studies are listed below.

02 / How it works

Mechanism at a glance

GLP-1GLP-1Targeted
GIPGIP—
GCGglucagon—
AMYamylin—
OTHOther targets—
Explore the hormone anatomy ↗
03 / Development

Obesity stage by formulation

Once-weekly oral peptideOral tablet · Once weekly
Phase 2EVOLVE-2 Phase 2b completed; topline expected by year-end 2026
Milestone → next

Latest: EVOLVE-2 Phase 2b is listed as completed, with topline results expected by year-end 2026. A separate Phase 2 weight-maintenance study was terminated after eight participants; the sponsor described a business decision not based on safety findings.

Next: EVOLVE-2 topline and the next development decision.

04 / Study records

Clinical study records

Obesity and weight-management studies appear first. Related-condition trials follow by phase, with focus labels to show what each study evaluates. Study stage and results reporting are listed separately. Results summarized above are identified as peer-reviewed or sponsor reported. Otherwise, the label states whether results were posted to a registry or reported in the linked source.

Obesity and weight-management studies

Phase 2 studies2 records

Phase 2b

EVOLVE-2 · NCT07281937

Weight management
Study: CompletedResults: No registry results posted yetStatus reviewed November 2026

A 20-week study of once-weekly oral VRB-101 in adults with obesity or overweight plus weight-related comorbidities; the registry lists the study as completed.

Phase 2

VRB-101-202 · weight maintenance

Weight maintenance
Study: TerminatedResults: No registry results posted yetStatus reviewed November 2026

Separate from EVOLVE-2. Terminated after eight participants. The sponsor stated this was a business decision and not based on safety findings. This study termination does not establish termination of the full program.